Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

The Indian Council of Medical Research has dropped the use of convalescent plasma from the recommended treatment guidelines for Covid-19.The National Task Force of the ICMR, along with experts from the Health Ministry, periodically updates guidelines on recommended modes of treatment.&nbsp;
Though a trial by the ICMR on 400 patients last year&nbsp;had found no significant benefit from the use of plasma it continued to find a place in the recommended guidelines.Registered Doctors anywhere, however, aren&rsquo;t bound by the Task Force recommendations.
Several other international trials had also found no benefit from plasma therapy.

ICMR drops plasma therapy from Covid-19 treatment guidelines

The Indian Council of Medical Research has dropped the use of convalescent plasma from the recommended treatment guidelines for Covid-19. The National Task Force of the ICMR, along with experts from the Health Ministry, periodically updates guidelines on recommended modes of treatment.&nbsp;
Though a trial by the ICMR on 400 patients last year&nbsp;had found no significant benefit from the use of plasma it continued to find a place in the recommended guidelines. Registered Doctors anywhere, however, aren&rsquo;t bound by the Task Force recommendations.
Several other international trials had also found no benefit from plasma therapy.

ICMR drops plasma therapy&nbsp;from&nbsp;Covid-19 cure guidelines
ICMR&nbsp;updates guidelines on modes of treatment&nbsp;
ICMR&nbsp;trial on 400 patients last year found no benefit of plasma&nbsp; Doctors however aren&rsquo;t bound by guidelines&nbsp;
Several international trial&nbsp;also&nbsp;found no benefit from plasma&nbsp;

The Indian Council of Medical Research has dropped the use of convalescent plasma from the recommended treatment guidelines for Covid-19. The National Task Force of the ICMR, along with experts from the Health Ministry, periodically updates guidelines on recommended modes of treatment.&nbsp;
Though a trial by the ICMR on 400 patients last year&nbsp;had found no significant benefit from the use of plasma it continued to find a place in the recommended guidelines. Registered Doctors anywhere, however, aren&rsquo;t bound by the Task Force recommendations.
Several other international trials had also found no benefit from plasma therapy.

On Ask The Doctor, Dr Vinay Gupta,&nbsp;Dr. Vinay Gupta, Lung/ICU Doctor, Faculty, Institute of Health Metrics and Evaluation, Covid 19 CMO, Amazon Care, says we shouldn't be focussing on drugs like Ivermection &amp; Remdesivir based on just anecdotal data. He adds, Ivermectin Is a dangerous drug and the doses required to kill Covid are very high which if used without medical supervision can cause liver and vital organ injury. Dr Kavita,&nbsp;Fellow, Brookings Institution, General Practitioner in Washington D.C.,&nbsp;says Remdesivir is not a miracle drug and indicriminate use can lead to more harm than good.

Ask The Doctor | Using Remdesivir & Ivermectin safe to use in Covid patients? Doctors explain

On Ask The Doctor, Dr Vinay Gupta,&nbsp;Dr. Vinay Gupta, Lung/ICU Doctor, Faculty, Institute of Health Metrics and Evaluation, Covid 19 CMO, Amazon Care, says we shouldn't be focussing on drugs like Ivermection &amp; Remdesivir based on just anecdotal data. He adds, Ivermectin Is a dangerous drug and the doses required to kill Covid are very high which if used without medical supervision can cause liver and vital organ injury. Dr Kavita,&nbsp;Fellow, Brookings Institution, General Practitioner in Washington D.C.,&nbsp;says Remdesivir is not a miracle drug and indicriminate use can lead to more harm than good.

Plasma therapy could be dropped from clinical management protocol of Covid-19 as ICMR&rsquo;s expert panel found that the therapy wasn&rsquo;t beneficial in reducing the progression to severe disease or death of patients, a CNN-News18 report said quoting sources.
The Indian Council of Medical Research is expected to issue an advisory on the same in the next few days. India&rsquo;s national task force on Covid-19 management met on Friday, to review the convalescent plasma therapy for infected patients. The present guidelines allow &ldquo;off label" use of plasma therapy at the stage of early moderate disease, that is, within seven days of the onset of Covid-19 symptoms and if there is availability of donor plasma.
A group of 18 clinicians, scientists and public health professionals had recently written to the government, saying the &ldquo;irrational use&rdquo; of plasma therapy &ldquo;raises the possibility of more virulent strains&rdquo; of Sars-Cov-2, the virus that causes Covid-19. In their letter, the experts cited three studies &mdash; the ICMR-PLACID Trial, the Recovery Trial conducted by the University of Oxford, and Argentina&rsquo;s PlasmAr Trial &mdash; to argue that the country&rsquo;s existing guidelines on plasma therapy were not based on evidence.

Plasma therapy to be dropped from ICMR's Covid protocols?

Plasma therapy may be dropped from ICMR's Covid&nbsp;management&nbsp;protocols, say reports; experts argue it may not be effective

Plasma therapy could be dropped from clinical management protocol of Covid-19 as ICMR&rsquo;s expert panel found that the therapy wasn&rsquo;t beneficial in reducing the progression to severe disease or death of patients, a CNN-News18 report said quoting sources.
The Indian Council of Medical Research is expected to issue an advisory on the same in the next few days. India&rsquo;s national task force on Covid-19 management met on Friday, to review the convalescent plasma therapy for infected patients. The present guidelines allow &ldquo;off label" use of plasma therapy at the stage of early moderate disease, that is, within seven days of the onset of Covid-19 symptoms and if there is availability of donor plasma.
A group of 18 clinicians, scientists and public health professionals had recently written to the government, saying the &ldquo;irrational use&rdquo; of plasma therapy &ldquo;raises the possibility of more virulent strains&rdquo; of Sars-Cov-2, the virus that causes Covid-19. In their letter, the experts cited three studies &mdash; the ICMR-PLACID Trial, the Recovery Trial conducted by the University of Oxford, and Argentina&rsquo;s PlasmAr Trial &mdash; to argue that the country&rsquo;s existing guidelines on plasma therapy were not based on evidence.

On today's episode of Ask The Doctor,&nbsp;Dr. Rakesh K Mishra, Advisor, Centre for Cellular and Molecular Biology (CCMB) against Covid, explains why plasma therapy for Covid&nbsp;patients is a desperate measure. He adds, plasma therapy has been around for years but it is never considered a standard treatment, patients who are administered plasma are at risk from&nbsp;other elements that might be present in the blood of the donor.

Ask The Doctor l Is plasma therapy essential in fighting Covid? Dr Rakesh Mishra explains

On today's episode of Ask The Doctor,&nbsp;Dr. Rakesh K Mishra, Advisor, Centre for Cellular and Molecular Biology (CCMB) against Covid, explains why plasma therapy for Covid&nbsp;patients is a desperate measure. He adds, plasma therapy has been around for years but it is never considered a standard treatment, patients who are administered plasma are at risk from&nbsp;other elements that might be present in the blood of the donor.

The Delhi Police launched 'Life Saving Plasma Donors' Data Bank' on the official website to help families of Covid patients find convalescent plasma easily. The force is now preparing an extensive data bank of willing donors and connecting them with patients.
With the help of this digital data bank, families of Covid patients who have been recommended plasma therapy will be able to immediately contact the donors, Delhi Police said in a release.
A tab called "Donate Plasma, Save Lives" has been added to the website. This tab when clicked opens up a window with two options- one for donors and one for those requesting plasma.
Clicking on either opens up a form that lets donors and recipients register.

Delhi Police launches data bank of plasma donors to help families of Covid patients

Delhi Police launches plasma donors data bank
Data bank to help increase access to plasma
Families can connect with donors without losing time
Donors &amp; recipients can fill simple form &amp; register&nbsp;
&nbsp;

The Delhi Police launched 'Life Saving Plasma Donors' Data Bank' on the official website to help families of Covid patients find convalescent plasma easily. The force is now preparing an extensive data bank of willing donors and connecting them with patients.
With the help of this digital data bank, families of Covid patients who have been recommended plasma therapy will be able to immediately contact the donors, Delhi Police said in a release.
A tab called "Donate Plasma, Save Lives" has been added to the website. This tab when clicked opens up a window with two options- one for donors and one for those requesting plasma.
Clicking on either opens up a form that lets donors and recipients register.

Master Blaster Sachin&nbsp;Tendulkar who turned 48 on Saturday urged his fans to donate blood for plasma therapy if they had recovered from the Covid-19 disease. Tendulkar&nbsp;who has recently&nbsp;recovered from the Coronavirus&nbsp;also informed that he too shall donate his blood for plasma therapy. Thanking his fans for the birthday wishes, the cricket icon posted a video of himself on his Twitter account. The batting great who requested people to come forward for plasma donation said that the doctors had given him a message that if plasma is given at the right time then the patients can recover faster. Tendulkar&nbsp;was hospitalised, after he contracted the Covid-19 disease last month.&nbsp;&nbsp;

After recovery from Covid-19, Sachin Tendulkar to donate plasma 

Master Blaster Sachin&nbsp;Tendulkar who turned 48 on Saturday urged his fans to donate blood for plasma therapy if they had recovered from the Covid-19 disease.&nbsp;

Sachin Tendulkar&nbsp;recently recovered from Covid Tendulkar&nbsp;announces to donate plasma Tendulkar&nbsp;urges fans to donate plasma, if permissible

Master Blaster Sachin&nbsp;Tendulkar who turned 48 on Saturday urged his fans to donate blood for plasma therapy if they had recovered from the Covid-19 disease. Tendulkar&nbsp;who has recently&nbsp;recovered from the infection&nbsp;informed that he too shall donate his plasma&nbsp;for therapy, as and when doctors allow him. Tendulkar&nbsp;was hospitalised, after he contracted the Covid-19 disease last month.&nbsp;&nbsp;

Plasma therapy doesn't reduce Covid deaths: ICMR

Use of convalescent plasma therapy in coronavirus-infected patients does not help in reducing mortality or progression to severe Covid-19, an ICMR-fudned&nbsp;study has found

Use of convalescent plasma therapy in coronavirus-infected patients does not help in reducing mortality or progression to severe Covid-19, a multi-centric study funded by the Indian Council of Medical Research has found. The study was conducted across 39 public and private hospitals across India between April 22 to July 14. The study trial included 464 moderately ill coronavirus infected hospitalised patients, of whom 235 were given plasma along with best of standard care while 229 received only standard care. The study found that there was no difference in 28-day mortality or progression to severe disease.

New Delhi, PTI: Use of convalescent plasma therapy in coronavirus-infected patients does not help in reducing mortality or progression to severe Covid-19, a multi-centric study funded by the Indian Council of Medical Research (ICMR) has found.
The 'open-label parallel-arm phase II multicentre randomized controlled trial' (PLACID Trial) was conducted across 39 public and private hospitals across India between April 22 to July 14 to investigate the effectiveness of convalescent plasma (CP) for the treatment of Covid-19, it said.
The convalescent plasma (CP) therapy involves taking antibodies from the blood of a person who has recovered from Covid-19 and transfusing those antibodies into an active coronavirus patient to help kickstart the immune system to fight the infection.
A total of 464 participants (moderately ill Covid-19 patients admitted to hospitals) were enrolled for the study, which has not yet been peer-reviewed and has appeared on medRxiv, a preprint server.
The National Task Force for Covid-19, a committee formed by the ICMR to respond to the pandemic, has reviewed and approved this study, it said.
The Clinical Management Protocols for Covid-19 issued by the Union Health Ministry on June 27 allowed use of convalescent plasma (Off label) for treating coronavirus-infected patients in moderate stage of the illness under "investigational therapies"
This authorisation has been paralleled by questionable practices such as calls for donors on social media, and the sale of CP on the black market with exorbitant price tags in India, the study said.
Additionally, although CP is a safe therapeutic modality, plasmapheresis, plasma storage and NAb measurement are all resource-intensive processes, with a limited number of institutes in the country having the capacity to undertake these activities in a quality-assured manner.
"The CP was not associated with reduction in mortality or progression to severe Covid-19," the study said, adding this trial has high generalisability and approximates real-life setting of CP therapy in settings with limited laboratory capacity.
A prior measurement of neutralising antibody titres in donors and participants may further clarify the role of CP in management of Covid-19, it said.
The study trial included 464 moderately ill coronavirus infected hospitalised patients, of whom 235 were given convalescent plasma along with best of standard care while 229 received only standard care, as per the study.
Those in the intervention arm received two doses of 200 ml of CP, transfused 24 hours apart, in addition to the BSC (best standard of care). The two plasma units were collected preferably from different donors depending on the availability and ABO compatibility to increase chances of receiving CP with NAb, it said.
"The PLACID trial results indicate that there was no difference in 28-day mortality or progression to severe disease among moderately ill Covid-19 patients treated with CP along with BSC compared to BSC alone," the study said.

plasma

Categories